|
FR22934E
(fr)
|
1919-07-19 |
1921-09-06 |
Albert Jean Baptiste Hanotelle |
Sifflet électro-automoteur perfectionné pour répétition des signaux sur la locomotive
|
|
US5250534A
(en)
|
1990-06-20 |
1993-10-05 |
Pfizer Inc. |
Pyrazolopyrimidinone antianginal agents
|
|
GB9401090D0
(en)
|
1994-01-21 |
1994-03-16 |
Glaxo Lab Sa |
Chemical compounds
|
|
WO1998038168A1
(en)
|
1997-02-27 |
1998-09-03 |
Tanabe Seiyaku Co., Ltd. |
Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
|
|
EP0977756A1
(en)
|
1997-04-25 |
2000-02-09 |
Pfizer Limited |
PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
|
|
PL339836A1
(en)
|
1998-02-19 |
2001-01-02 |
Eisai Co Ltd |
Phtalazine compounds and therapeutic agents suitable to treat erection disorders
|
|
CN1332943C
(zh)
|
1998-07-08 |
2007-08-22 |
萨诺费－阿文蒂斯德国有限公司 |
硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
|
|
GB9823101D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9925962D0
(en)
|
1999-11-02 |
1999-12-29 |
Novartis Ag |
Organic compounds
|
|
CA2406947A1
(en)
|
2000-04-19 |
2001-10-25 |
Johns Hopkins University |
Methods for prevention and treatment of gastrointestinal disorders
|
|
CA2411008C
(en)
|
2000-06-07 |
2006-04-11 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
EP1366049B1
(en)
|
2000-06-23 |
2006-06-21 |
Lilly Icos LLC |
Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives
|
|
ES2269408T3
(es)
|
2000-06-23 |
2007-04-01 |
Lilly Icos Llc |
Inhibidores de fosfodiesterasa especifica de gmp ciclico.
|
|
EP1313736B1
(en)
|
2000-06-26 |
2005-07-27 |
Lilly Icos LLC |
Condensed pyrazindione derivatives as inhibitors of pde5
|
|
EP1335923B1
(en)
|
2000-10-03 |
2006-07-12 |
Lilly Icos LLC |
Condensed pyridoindole derivatives
|
|
ATE337320T1
(de)
|
2000-11-06 |
2006-09-15 |
Lilly Icos Llc |
Indolderivate als pde5-inhibitoren
|
|
HU229938B1
(en)
|
2001-05-03 |
2015-01-28 |
Hoffmann La Roche |
Pharmaceutical dosage form of amorphous nelfinavir mesylate
|
|
GB0202254D0
(en)
|
2002-01-31 |
2002-03-20 |
Pfizer Ltd |
Prevention of scarring
|
|
US7091207B2
(en)
|
2002-05-22 |
2006-08-15 |
Virginia Commonwealth University |
Method of treating myocardial infarction with PDE-5 inhibitors
|
|
WO2004037183A2
(en)
|
2002-10-22 |
2004-05-06 |
Harbor-Ucla Research And Education Institute |
Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
|
|
GB0318094D0
(en)
|
2003-08-01 |
2003-09-03 |
Pfizer Ltd |
Novel combination
|
|
US20060094744A1
(en)
|
2004-09-29 |
2006-05-04 |
Maryanoff Cynthia A |
Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
|
|
WO2007050585A2
(en)
|
2005-10-24 |
2007-05-03 |
The Johns Hopkins University |
Use of a nitric oxide synthase modulator for the treatment of cardiac indications
|
|
EP2302395B1
(en)
*
|
2006-06-07 |
2015-04-15 |
Health Diagnostic Laboratory, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
|
CN102056907B
(zh)
|
2008-04-04 |
2014-12-31 |
武田药品工业株式会社 |
杂环衍生物及其用途
|
|
GB201114901D0
(en)
|
2011-08-26 |
2011-10-12 |
King S College London |
Vascular treatments
|
|
EP2594270A3
(en)
|
2011-11-18 |
2013-07-31 |
BIP Patents |
The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
|
|
EP2938343B1
(en)
|
2012-12-21 |
2018-09-12 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating calcific aortic valve stenosis
|
|
KR102456567B1
(ko)
|
2013-08-09 |
2022-10-19 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
|
CN107580495A
(zh)
|
2015-05-06 |
2018-01-12 |
拜耳制药股份公司 |
单独和与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于治疗伴随系统性硬化症(SSc)的指溃疡(DU)的用途
|
|
JP7057365B2
(ja)
|
2016-09-30 |
2022-04-19 |
ゼナメッド コーポレーション |
ミドドリンの組成物およびその使用方法
|
|
EP4620525A3
(en)
|
2016-12-14 |
2025-12-03 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|